Search clinical trials for: Tumor Purged/CD25 Depleted Lymphocytes

Total 302 results

Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Oncovir, Inc.; Phase...

Recruiting

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Northwest Biotherapeutics; Brain Tumor Funders Collaborative

Withdrawn

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Small Cell Glioblastoma | Giant Cell Glioblastoma

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Myeloproliferative Neoplasm | T-Cell Non-Hodgkin Lymphoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.; Prometheus Inc.

Completed

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Skin Cancer | Melanoma (Skin)

United States
Lund University Hospital

Completed

Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Sweden
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
University Health Network, Toronto

Completed

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Metastatic, Stage III or Stage IV, Melanoma

Canada
Hoag Memorial Hospital Presbyterian

Completed

Biological Therapy in Treating Patients With Metastatic Cancer

Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Vall d'Hebron Institute of Oncology
Banc de Sang i Teixits

Recruiting

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors (NEXTGENTIL-ACT)

Epithelial Tumors, Malignant | Malignant Solid Tumor

Spain
Sidney Kimmel Cancer Center at Thomas Jefferson...

Withdrawn

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Recurrent Mycosis Fungoides and Sezary Syndrome | Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IIB Mycosis Fungoides and Sezary Syndrome | Stage IIIA Mycosis Fungoides and Sezary Syndrome | Stage IIIB Mycosis Fungoides and Sezary Syndrome | Stage IVA Mycosis Fungoides and Sezary Syndrome | Stage...
National Cancer Institute (NCI)

Completed

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Anti-p53 TCR-Gene

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Malignant Solid Neoplasm | Melanoma | Colitis | Lung Non-Small Cell Carcinoma | Malignant Genitourinary System Neoplasm

United States
Roswell Park Cancer Institute

Completed

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Fanconi Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Aplastic Anemia

United States
James Isaacs, MD

Not yet recruiting

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIID Melanoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Malignant Neoplasm | Myeloproliferative Neoplasm | Indolent Non-Hodgkin Lymphoma | Acute Myeloid Leukemia in Remission | Refractory Anemia | Refractory Anemia With... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Giant Cell Glioblastoma

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
St. Luke's Medical Center

Completed

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Brain and Central Nervous System Tumors

United States
Regionshospitalet Viborg, Skive

Completed

The Luteal Phase After GnRHa Trigger - a Proof of Concept Study

Infertility | Progesterone Levels

Denmark
University of Rochester

Completed

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Kidney Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Squamous Cell Carcinoma of Head and Neck | Metastatic Squamous Cell Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.

Active, not recruiting

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Metastatic Melanoma

United States
University of California, San Diego
National Cancer Institute (NCI)

Terminated

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
Richard Wu
Iovance Biotherapeutics, Inc.

Active, not recruiting

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Locally Advanced Melanoma | Stage IV Melanoma | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Castleman Disease | Lymphangioleiomyomatosis | Digestive System Carcinoma | Malignant Neoplasm | Recurrent Breast Carcinoma | Recurrent Thyroid Gland Carcinoma | Metastatic Urothelial Carcinoma | Malignant Female Reproductive System Neoplasm | Neurofibromatosis Type 2 | Recurrent Adult Soft Tissue Sarcoma and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
Joseph Baar, MD, PhD

Completed

Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients

Breast Cancer | Metastatic Breast Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
GlaxoSmithKline; Novartis

Completed

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 Positive

United States

Search clinical trials for: Tumor Purged/CD25 Depleted Lymphocytes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations